Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT

SUBSIDIARY'S PRODUCT — ZS-2000 FULLY AUTOMATIC BIOCHEMICAL ANALYZER OBTAINING MEDICAL DEVICE REGISTRATION CERTIFICATE FOR MARKET LAUNCH

This announcement is made by Biosino Bio-Technology and Science Incorporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the Shareholders of the Company and potential investors with information regarding the latest business development of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that the ZS-2000 Fully Automatic Biochemical Analyzer, independently developed by Biosino Medical Instrument Technology (Jinan) Co., Ltd.(中生醫療器械科技(濟南)有限公司) ("**Biosino Jinan**"), a subsidiary of the Company, has recently obtained the Medical Device Registration Certificate for the PRC (Registration Certificate No.: Lu Xie Zhu Zhun 20262220227) issued by the Shandong Medical Products Administration of the People's Republic of China (the "**PRC**"), marking that the product is qualified for legal launch, sale and use within the territory of the PRC.

1. Basic Information of the Product

Product Name: Fully Automatic Biochemical Analyzer
Model: ZS-2000
Registration Certificate No.: Lu Xie Zhu Zhun 20262220227
Validity Period of Registration: 16 April 2026 to 15 April 2031
Issuing Authority: Shandong Medical Products Administration

Intended Use: When used in conjunction with the supporting reagents, the product is clinically used for the quantitative analysis of clinical chemical components in human serum, plasma, whole blood, urine, cerebrospinal fluid, seminal plasma, and fecal samples, including liver function, renal function, ion metabolism, blood glucose, blood lipids, myocardial enzyme spectrum, and immunochemical parameters. When optionally equipped with an electrolyte analysis module, it can be used for the determination of potassium ions, sodium ions, and chloride ions electrolyte items in human serum

The ZS-2000 Fully Automatic Biochemical Analyzer is primarily used for clinical biochemical testing and can be widely applied in hospital clinical laboratories, third-party medical laboratories, and other medical testing institutions. It features high throughput, automation, and intelligence and others, which help improve testing efficiency and reduce operational costs.

2. Other Relevant Information of the Product

The obtaining of this registration certificate not only signifies a further enhancement of the Group's technological strength in the field of high-end biochemical analytical instruments, but also marks the Group's continuous improvement of its product portfolio in terms of the "instrument + reagent" integrated solution, which will help enhance the market competitiveness and brand influence of the Group's products.

The Board is of the view that the successful market launch of the ZS-2000 Fully Automatic Biochemical Analyzer, together with the collaborative launch of the ZS-8600 chemistry-immunoassay integrated system, will assist the Group in further expanding the domestic medical testing market and promoting the sales of related supporting reagent products, which is in line with the Group's long-term development strategy.

3. Impact on the Company and Risk Warning

The obtaining of the above registration certificate is expected to have a positive impact on the financial position and operating results of the Group for the current year. The actual sales performance of the product in market may be subject to uncertainties arising from various factors including market conditions, bidding process, regulatory policies, competition landscape and macroeconomy.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, China, 20 April 2026

As at the date of this announcement, the members of the Board comprise:

Chairman, President and Executive Director
Mr. Chen Peng (陳鵬先生)

Vice Chairman and Executive Director
Mr. Li Zhonghua (李忠華先生)

Executive Director
Mr. Chen Zhengyong (陳正永先生)

Non-executive Director
Ms. Kang Rui (康睿女士)

Independent non-executive Directors
Prof. Shen Jiangang (沈劍剛教授), Mr. Fan Xiaoliang (范曉亮先生) and Prof. Jin Tengchuan (金騰川教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the "Latest Listed Company Announcements" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company's website at www.zhongsheng.com.cn.